Antimicrobial Agents Practice Questions

Q: Which of the following is recommended as a dual-active drug targeting both HBV and HIV?

Tenofovir. **Explanation:** The management of HIV/HBV co-infection requires drugs that exhibit potent activity against both viruses to prevent the development of resistance and simplify dosing regimens. **Why Tenofovir is Correct:** Tenofovir (available as Tenofovir Disoproxil Fumarate - TDF or Tenofovir Alafenamide - TAF) is a **Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI)**. It inhibits the reverse transcriptase enzyme in HIV and the DNA polymerase in HBV. It is considered a first-line agent for both infections due to its high genetic barrier to resistance and superior efficacy. In co-infected patients, Tenofovir is almost always included as part of the ART (Antiretroviral Therapy) backbone. **Analysis of Incorrect Options:** * **Entecavir (A):** While it is a potent anti-HBV drug, it has weak activity against HIV. Using it in a co-infected patient not on ART can lead to the **M184V mutation** in HIV, causing cross-resistance to Lamivudine. * **Adefovir (B):** It is used for HBV but is ineffective against HIV at the doses used for hepatitis. Higher doses required for HIV are highly nephrotoxic. * **Zidovudine (D):** This is an NRTI used for HIV (especially in pregnancy/PMTCT), but it has **no activity** against the HBV virus. **High-Yield Clinical Pearls for NEET-PG:** * **Dual-active drugs:** Tenofovir, Lamivudine (3TC), and Emtricitabine (FTC) are the three main drugs active against both HIV and HBV. * **The "Flare" Phenomenon:** If a dual-active drug like Tenofovir is discontinued in a co-infected patient, it can lead to a life-threatening "rebound" or flare of Hepatitis B. * **Preferred Regimen:** The WHO and NACO recommend a TDF + 3TC (or FTC) + Dolutegravir (DTG) regimen for most HIV/HBV co-infected patients.

Q: Which of the following anti-influenza drugs can cause Livedo reticularis?

Amantadine. **Explanation:** **Amantadine** is the correct answer. It is an M2 ion channel blocker primarily used against Influenza A (though now largely obsolete due to widespread resistance) and in the management of Parkinson’s disease. **Mechanism of Livedo Reticularis:** Amantadine causes **Livedo reticularis**—a purplish, net-like pattern of vascular discoloration on the skin—by promoting the release of catecholamines from peripheral nerve terminals. This leads to localized vasoconstriction of dermal vessels and subsequent venous stasis. This side effect is usually benign and reversible upon discontinuation of the drug. **Analysis of Incorrect Options:** * **Rimantadine (Option B):** A derivative of amantadine with a similar mechanism (M2 blocker). While it shares some side effects, it has a much lower incidence of CNS effects and is significantly less associated with Livedo reticularis compared to amantadine. * **Zanamivir and Laninamivir (Options A & D):** These are **Neuraminidase Inhibitors**. Their side effect profiles are different; Zanamivir is administered via inhalation and can cause bronchospasm, while Laninamivir is a long-acting neuraminidase inhibitor. Neither is associated with Livedo reticularis. **High-Yield Clinical Pearls for NEET-PG:** * **Amantadine Triple Action:** It acts as an antiviral, an antiparkinsonian agent (increases dopamine release), and an NMDA antagonist. * **Other Side Effects:** It can cause ankle edema and "Amantadine-induced psychosis" (hallucinations). * **Livedo Reticularis Differential:** Apart from Amantadine, it is also seen in systemic conditions like SLE, Polyarteritis Nodosa (PAN), and Antiphospholipid Syndrome (APS). * **Neuraminidase Inhibitors:** Oseltamivir (oral), Zanamivir (inhaled), and Peramivir (IV) are active against both Influenza A and B.

Q: A healthcare worker has a needle-stick injury exposure to HIV. Which of the following drug regimens is indicated for post-exposure prophylaxis?

Zidovudine + Lamivudine + Indinavir for 4 weeks. ### Explanation **Correct Option: A (Zidovudine + Lamivudine + Indinavir for 4 weeks)** Post-exposure prophylaxis (PEP) for HIV is categorized based on the severity of exposure. For **high-risk exposures** (e.g., deep needle-stick injuries with a high viral load source), an expanded regimen consisting of **three drugs** is indicated. The combination of two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) like **Zidovudine and Lamivudine** plus a Protease Inhibitor (PI) like **Indinavir** (or Lopinavir/Ritonavir) is the classic recommendation to ensure maximum viral suppression. The duration of treatment is strictly **4 weeks (28 days)**. **Analysis of Incorrect Options:** * **Option B:** Nevirapine (an NNRTI) is contraindicated in PEP because it carries a high risk of severe hepatotoxicity and Stevens-Johnson Syndrome (SJS) in HIV-negative individuals. * **Option C:** Zidovudine and Stavudine should never be used together. Both are thymidine analogs that compete for the same phosphorylation pathway, leading to **pharmacological antagonism**. * **Option D:** This two-drug regimen (Basic Regimen) was previously used for low-risk exposures. However, current guidelines (WHO/NACO) now favor a three-drug regimen for all significant exposures to simplify protocols and increase efficacy. **High-Yield Clinical Pearls for NEET-PG:** * **Timing:** PEP should be started as soon as possible, ideally within **2 hours**, and definitely within **72 hours** of exposure. * **Current NACO/WHO Preferred Regimen:** Tenofovir (TDF) + Lamivudine (3TC) + Dolutegravir (DTG). * **Monitoring:** Baseline HIV testing should be done, followed by repeat testing at 6 weeks, 3 months, and 6 months. * **Zidovudine Side Effects:** Most common is anemia (bone marrow suppression) and GI intolerance.

Q: Metronidazole is indicated in the treatment of which one of the following conditions?

Helicobacter pylori infection. **Explanation:** **Metronidazole** is a nitroimidazole derivative that acts by forming reactive cytotoxic intermediates that cause DNA strand breakage. It is primarily effective against **obligate anaerobes** and certain **protozoa**. **1. Why Option D is Correct:** *Helicobacter pylori* is a microaerophilic, Gram-negative bacterium. Metronidazole is a core component of several multidrug regimens (such as the **Bismuth-based Quadruple Therapy** or the **Clarithromycin-based Triple Therapy**) used to eradicate *H. pylori*. It is particularly useful in patients allergic to penicillin or in regions where resistance patterns allow its use. **2. Why Other Options are Incorrect:** * **A & B (Traveller's Diarrhea / E. coli):** These are most commonly caused by Enterotoxigenic *E. coli* (ETEC). The drugs of choice are **Fluoroquinolones** (like Ciprofloxacin) or **Rifaximin**. Metronidazole has no activity against aerobic Gram-negative rods like *E. coli*. * **C (Cryptosporidium):** This protozoan causes self-limiting diarrhea in immunocompetent hosts but severe diarrhea in AIDS patients. The drug of choice is **Nitazoxanide**. Metronidazole is ineffective against *Cryptosporidium*. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Metronidazole is the DOC for **Pseudomembranous colitis** (mild-to-moderate *C. difficile*), **Amoebiasis**, **Giardiasis**, **Trichomoniasis**, and **Bacterial Vaginosis**. * **Disulfiram-like Reaction:** Patients must avoid alcohol while on Metronidazole due to the inhibition of aldehyde dehydrogenase. * **Side Effects:** Metallic taste, nausea, and peripheral neuropathy (with long-term use). * **Mechanism:** It requires reductive activation of the nitro group by the enzyme **pyruvate:ferredoxin oxidoreductase (PFOR)**, found only in anaerobes.

Q: A 45-year-old man is placed on an antifungal agent for systemic infection and is noted to have decreased serum leukocyte and platelet counts. Bone marrow suppression is a common adverse effect of which of the following drugs?

Flucytosine. **Explanation:** **Flucytosine (5-Fluorocytosine)** is the correct answer. It is a pyrimidine antimetabolite that acts as a prodrug. Inside the fungal cell, it is converted by the enzyme **cytosine deaminase** into **5-fluorouracil (5-FU)**, which inhibits DNA and protein synthesis. While human cells lack cytosine deaminase, the intestinal flora can convert some flucytosine into 5-FU systemically. This leads to significant **bone marrow suppression** (leukopenia, thrombocytopenia, and anemia), which is its most characteristic and dose-limiting adverse effect. **Analysis of Incorrect Options:** * **Griseofulvin (A):** Primarily used for dermatophytosis. Its common side effects include headaches, GI upset, and photosensitivity. It is an inducer of Cytochrome P450. * **Terbinafine (B):** An allylamine that inhibits squalene epoxidase. It is most commonly associated with GI distress, taste disturbances, and rarely, hepatotoxicity, but not typically bone marrow suppression. * **Fluconazole (C):** An azole that inhibits ergosterol synthesis. It is generally well-tolerated; its main concerns are GI upset and inhibition of CYP3A4 enzymes. **High-Yield Clinical Pearls for NEET-PG:** * **Synergy:** Flucytosine is almost always used in combination with **Amphotericin B** (especially for Cryptococcal meningitis) to prevent the rapid development of resistance. * **Mechanism:** It inhibits **thymidylate synthase**, thereby halting DNA synthesis. * **Monitoring:** Patients on Flucytosine require regular **Complete Blood Counts (CBC)** to monitor for hematological toxicity. * **Renal Impairment:** Toxicity is significantly increased in patients with renal failure, as the drug is excreted unchanged by the kidneys.

Q: Which one of the following is a nucleoside analog reverse transcriptase inhibitor?

Zidovudine. ### Explanation **Correct Answer: C. Zidovudine** **Mechanism of Action:** Zidovudine (AZT) is a **Nucleoside Reverse Transcriptase Inhibitor (NRTI)** [2]. It is a structural analog of thymidine [1]. To become active, it must undergo intracellular phosphorylation by host cell kinases into its triphosphate form [1, 2]. It then competes with natural nucleotides for incorporation into the viral DNA chain by the enzyme **Reverse Transcriptase** [1]. Once incorporated, it causes **premature chain termination** because it lacks the 3'-OH group necessary for forming a phosphodiester bond [1]. **Analysis of Incorrect Options:** * **A & B (Efavirenz and Nevirapine):** These are **Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)** [2]. Unlike NRTIs, they do not require phosphorylation and do not compete with nucleotides. Instead, they bind directly to a non-catalytic "pocket" on the Reverse Transcriptase enzyme, causing a conformational change that inhibits its activity. * **D (Saquinavir):** This is a **Protease Inhibitor (PI)**. It inhibits the viral protease enzyme (HIV-1 protease), preventing the cleavage of gag-pol polyproteins into functional mature proteins, resulting in the production of immature, non-infectious virions. **Clinical Pearls for NEET-PG:** * **Zidovudine Side Effects:** The most characteristic side effect is **bone marrow suppression** (anemia and neutropenia). It is also associated with **myopathy** and nail hyperpigmentation. * **Prevention of Mother-to-Child Transmission (PMTCT):** Zidovudine was the first drug used to reduce vertical transmission of HIV. * **Mitochondrial Toxicity:** NRTIs can inhibit mitochondrial DNA polymerase-gamma, leading to lactic acidosis and hepatic steatosis (Stavudine > Zidovudine) [1]. * **Tenofovir:** Note that Tenofovir is a **Nucleotide** analog (already has one phosphate group), whereas Zidovudine is a **Nucleoside** analog.

Q: Which of the following conditions is NOT typically treated with azoles?

Cryptococcal meningitis. The correct answer is **Cryptococcal meningitis** because, while azoles (specifically Fluconazole) are used in the maintenance phase, they are **not** the treatment of choice for the induction phase of this life-threatening condition [1]. **1. Why Cryptococcal Meningitis is the correct answer:** The standard of care for the induction phase of Cryptococcal meningitis is a combination of **Amphotericin B and Flucytosine** [1]. Azoles are fungistatic and do not achieve rapid clearance of the fungus from the CSF. Although Fluconazole is used for long-term suppression (maintenance), it is insufficient as a primary treatment for the acute, severe stage of the disease [1]. **2. Why the other options are incorrect:** * **Chromomycosis:** Itraconazole is a first-line agent for this subcutaneous fungal infection, often combined with surgery or cryotherapy. * **Histoplasmosis:** Itraconazole is the drug of choice for mild-to-moderate cases [1]. Amphotericin B is reserved only for severe or disseminated disease. * **Paracoccidioidomycosis:** Itraconazole is considered the gold standard for treatment due to its high efficacy and lower toxicity compared to older sulfonamides. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for most systemic mycoses:** Itraconazole (e.g., Blastomycosis, Sporotrichosis, Histoplasmosis) [1]. * **Voriconazole:** DOC for **Invasive Aspergillosis** [3]. * **Fluconazole:** Notable for excellent CSF penetration [2], but its fungistatic nature limits its use in the induction phase of meningitis. * **Ketoconazole:** Now rarely used systemically due to its side effect profile (Cushing’s syndrome treatment, hepatotoxicity, and inhibition of steroidogenesis).

Q: Which of the following is NOT a known side effect of dapsone?

Myopathy. **Explanation:** Dapsone (Diaminodiphenyl sulfone) is a cornerstone in the treatment of leprosy and *Pneumocystis jirovecii* pneumonia. **Myopathy** is not a side effect of dapsone; it is more commonly associated with drugs like statins, colchicine, or zidovudine (AZT). **Analysis of Options:** * **Hemolytic Anemia (Option A):** This is the most common dose-related side effect. Dapsone causes oxidative stress on red blood cells. It is particularly severe in patients with **G6PD deficiency**, making G6PD screening essential before starting therapy. * **Hepatitis (Option C):** Dapsone can cause drug-induced liver injury, ranging from mild transaminitis to severe cholestatic jaundice as part of a hypersensitivity reaction. * **Infectious Mononucleosis-type Syndrome (Option D):** Also known as **"Dapsone Syndrome,"** this is a severe hypersensitivity reaction occurring 4–6 weeks after starting therapy. It is characterized by a triad of fever, malaise, and lymphadenopathy, often accompanied by jaundice and exfoliative dermatitis. It mimics infectious mononucleosis but is drug-induced. **High-Yield Clinical Pearls for NEET-PG:** * **Methemoglobinemia:** Dapsone frequently causes methemoglobinemia (presents as "chocolate-colored blood" and cyanosis). * **Lepra Reactions:** Dapsone is used in MDT for leprosy but does not prevent Type 1 or Type 2 lepra reactions. * **Mechanism:** It inhibits dihydropteroate synthase (folate synthesis inhibitor), similar to sulfonamides. * **Agranulocytosis:** A rare but life-threatening idiosyncratic reaction.

Q: All of the following are used in the treatment of Pneumocystis jirovecii pneumonia except?

Fluoroquinolones. **Explanation:** *Pneumocystis jirovecii* is a unique unicellular fungus that causes opportunistic pneumonia (PCP), primarily in immunocompromised patients (e.g., HIV/AIDS). Unlike most fungi, it lacks ergosterol in its cell membrane, making it resistant to standard antifungals like Amphotericin B or Azoles. **Why Fluoroquinolones are the Correct Answer:** Fluoroquinolones (e.g., Ciprofloxacin, Levofloxacin) act by inhibiting DNA gyrase and Topoisomerase IV in bacteria [1]. They have **no clinical activity** against *P. jirovecii*. Therefore, they are not used in the treatment or prophylaxis of PCP. **Analysis of Other Options:** * **Cotrimoxazole (Trimethoprim-Sulfamethoxazole):** This is the **drug of choice** for both treatment and prophylaxis of PCP [1, 5]. It works by inhibiting sequential steps in the folate synthesis pathway. * **Pentamidine:** An alternative agent used in patients who cannot tolerate Cotrimoxazole or in severe cases [2]. It is administered intravenously or via inhalation (though inhalation is less effective for treatment) [2]. * **Dapsone:** Often used in combination with Trimethoprim, it is an effective alternative for prophylaxis and mild-to-moderate treatment in patients with sulfonamide allergies. **High-Yield Clinical Pearls for NEET-PG:** 1. **First-line Treatment:** Cotrimoxazole (High dose: 15–20 mg/kg/day of TMP component) [3]. 2. **Steroid Indication:** In HIV patients, if $PaO_2 35$ mmHg, add corticosteroids to prevent clinical worsening due to inflammation from dying organisms [3]. 3. **Other Alternatives:** Atovaquone (mild cases) and Clindamycin + Primaquine (moderate-to-severe cases). 4. **Prophylaxis:** Indicated in HIV patients when CD4 count falls below **200 cells/µL**.

Q: A 15-year-old boy presents with a two-day history of fever, altered sensorium, and a purpuric rash. On examination, he is stuporous, with a BP of 90/60 mmHg and extensive palpable purpura on his legs. Which of the following would be the most appropriate initial choice of antibiotic?

Penicillin G. ### Explanation The clinical presentation of fever, altered sensorium, and a characteristic **purpuric rash** (especially palpable purpura) in a young patient is highly suggestive of **Meningococcemia** (caused by *Neisseria meningitidis*). This is a medical emergency that can rapidly progress to Waterhouse-Friderichsen syndrome and septic shock. **1. Why Penicillin G is the Correct Answer:** Historically and for exam purposes, **Penicillin G** remains the drug of choice for confirmed meningococcal infections. While third-generation cephalosporins (like Ceftriaxone) are often used empirically in clinical practice to cover both *S. pneumoniae* and *N. meningitidis*, Penicillin G is the classic, highly effective treatment for susceptible strains of *N. meningitidis*. It has excellent bactericidal activity and achieves therapeutic concentrations in the CSF when the meninges are inflamed. **2. Why the Other Options are Incorrect:** * **Vancomycin (A):** Primarily used for MRSA or resistant *S. pneumoniae*. It does not provide adequate coverage for Gram-negative diplococci like *N. meningitidis*. * **Ciprofloxacin (C):** While used for **prophylaxis** in close contacts of a patient with meningococcal meningitis, it is not the first-line agent for the treatment of the acute disease. * **Gentamicin (D):** An aminoglycoside used for Gram-negative enteric bacilli. It has poor CSF penetration and is ineffective against *N. meningitidis*. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC) for Meningococcemia:** Penicillin G. * **DOC for Meningococcal Prophylaxis:** Rifampicin (most common), Ciprofloxacin, or Ceftriaxone. * **Classic Triad:** Fever, neck stiffness, and altered mental status (though the purpuric rash is the "giveaway" for Meningococcemia). * **Mechanism of Penicillin:** Inhibits bacterial cell wall synthesis by binding to Penicillin-Binding Proteins (PBPs) and inhibiting transpeptidation.

Question 1

Which of the following is recommended as a dual-active drug targeting both HBV and HIV?

Accepted Answer

Tenofovir

Answer

Entecavir

Answer

Adefovir

Answer

Zidovudine

Question 2

Which of the following anti-influenza drugs can cause Livedo reticularis?

Accepted Answer

Amantadine

Answer

Laninamivir

Answer

Rimantidine

Answer

Zanamivir

Question 3

A healthcare worker has a needle-stick injury exposure to HIV. Which of the following drug regimens is indicated for post-exposure prophylaxis?

Accepted Answer

Zidovudine + Lamivudine + Indinavir for 4 weeks

Answer

Zidovudine + Lamivudine + Nevirapine for 4 weeks

Answer

Zidovudine + Stavudine for 4 weeks

Answer

Zidovudine + Lamivudine for 4 weeks

Question 4

Metronidazole is indicated in the treatment of which one of the following conditions?

Accepted Answer

Helicobacter pylori infection

Answer

Traveller's diarrhea

Answer

Escherichia coli-induced diarrhoea

Answer

Cryptosporidium-induced diarrhea

Question 5

A 45-year-old man is placed on an antifungal agent for systemic infection and is noted to have decreased serum leukocyte and platelet counts. Bone marrow suppression is a common adverse effect of which of the following drugs?

Accepted Answer

Flucytosine

Answer

Griseofulvin

Answer

Terbinafine

Answer

Fluconazole

Question 6

Which one of the following is a nucleoside analog reverse transcriptase inhibitor?

Accepted Answer

Zidovudine

Answer

Efavirenz

Answer

Nevirapine

Answer

Saquinavir

Question 7

Which of the following conditions is NOT typically treated with azoles?

Accepted Answer

Cryptococcal meningitis

Answer

Chromomycosis

Answer

Histoplasmosis

Answer

Paracoccidioidomycosis

Question 8

Which of the following is NOT a known side effect of dapsone?

Accepted Answer

Myopathy

Answer

Hemolytic anemia

Answer

Hepatitis

Answer

Infectious mononucleosis type syndrome

Question 9

All of the following are used in the treatment of Pneumocystis jirovecii pneumonia except?

Accepted Answer

Fluoroquinolones

Answer

Pentamidine

Answer

Dapsone

Answer

Cotrimoxazole

Question 10

A 15-year-old boy presents with a two-day history of fever, altered sensorium, and a purpuric rash. On examination, he is stuporous, with a BP of 90/60 mmHg and extensive palpable purpura on his legs. Which of the following would be the most appropriate initial choice of antibiotic?

Accepted Answer

Penicillin G

Answer

Vancomycin

Answer

Ciprofloxacin

Answer

Gentamicin

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?